Clinical Trial Update: Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial updated results on preemptive Grazoprevir/Elbasvir treatment for donor HCV positive to recipient HCV negative kidney transplant recipie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Transplant Status
• Renal Failure

Drugs mentioned

• Grazoprevir/Elbasvir

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Renal Failure | Phase 4 | Status: COMPLETED | Results posted: 2020-02-26